Abstract In patients with nephropathic cystinosis, corneal crystals develop by one year of age; they progressively accumulate and eventually cause recurrent cemeat erosions and photophobia. After an In vitro study of cystinotic corneal stromal cells showed cystine depletion by cysteamine and after topical cysteamine was determined to be nontoxic in rabbits, we performed a controlled double-blind clinical trial of 10 mM cysteamine eyedrops in young patients with cystinosis, using one eye for treatment I N ncphropathic cystinosis, a rare lysosomal storage disease, cystine accumulates within cells to levels 50 to 100 times normaL ' · 3 The basic defect of this autosomal recessively inherited disorder is an impairment of normal carrier-mediated transport of cystine across the lysosomal membranc4-1 j obligate heterozygotes for the cystinosis gene have half the normal amount of lysosomal cystine transport. 8 In cystinotic cells, free nonprotein cystine, which is poorly soluble in an aqueous solution, reaches such high concentrations that it forms crystals in many tissues, including the kidneys, bone marrow, intestine, liver, spleen, pancreas, thyroid, lymph nodes, retinal pigment epithelium,9 conjunctiva, and corneas.
Intralysosomal cystine accumulation in cystinosis apparently interferes with the function of different organs at different rates, resulting in a characteristic sequence of clinical manifestations. Patients are normal at birth, but renal tubular Fanconi's syndrome develops between 6 and 18 months of age, with failure to reabsorb water, electrolytes, bicarbonate, glucose, phosphate, calcium, magnesium, amino acids, carnitine,'O and other small molecules. Consequently, infants often present with acidosis, dehydration, electrolyte imbalance, failure to grow, or hypophosphatemic rickets. Although the growth failure persists unless specific cystine-depleting therapy is given, the fluid, electrolyte, and nutrient deficiencies can be corrected by oral replacement therapy. This treatment, however, ha"s no effect on the renal glomerular deterioration that begins in the first years of life and progresses inexorably to end-stage kidney disease. Uremia generally occurs by 10 years of age, II requiring dialysis or renal transplantation. 12 In addition to renal damage, frequent complications of cystinosis include hypothyroidism '3 and hypohidrosis" in young patients and visual impairment, 9 diabetes mellitus, and neurologic deficits among older patients who have undergone renal transplantation. 15 In the cornea, cystine crystals generally appear by one year of agel and are pathognomonic of cystinosis.
From ( and the other as the central. Two children begun on the protocol before two years of age had a striking decrease in the number of corneal crystals in the cysteamine-treated eye wilhin four to five months of entering the study.
Cysteamine eyedrops appear to be safe and efficacious in the short-term treatment of patients with cystinosis who are under two years of age. The long-term value of such treatment and its effectiveness in older patients remain to be determined. (N Engl J Med 1987; 316:775-9.)
The corneal crystal accumulation progresses with age and is considered partly responsible for the photophobia, recurrent corneal erosions, and secondary blepha. rospasm that complicate longstanding cyslinosis. 9 In addition to replacement of renal losses, the therapy of nephropathic cystinosis now includes oral administration of cysteamine (,B-mercaptocthylamine), a free thiol with a marked cystine-depleting ability. I. Cysteamine has heen shown to stahilize renal glomcr· ular function and to improve growth in children with cystinosis.1 7 However, no retardation in the rate of corneal crystal accumulation has been attributed to systemic cysteamine after as long as eight years of therapy.
We determined that cysteamine effectively reduced the cystine content of cystinotic corneal cells in cui· ture. A double-blind, placebo-controlled trial of topical cysteamine eyedrops was then initiated to study the effects on corneal crystal formation in two young children (less than two years of age) with nephropathie cystinosis.
METHODS

Tissue Culture
A penetrating keratoplasty was pt'rformed on a 13-year-old boy with nephropathic cystinosis to achieve partial relief of inC"apacitating photophobia and blepharospasm caused by recurrent corneal erosions. IA The corneal stromal cells culturrd from the keratoplasty specimen were grown to cnnnuence in Eaglc's minimal 6Scnlial medium (GIBCO, Grand Island, N.Y.) containing 10 Pf!rcent fetalcalf serum. 19 Cultures {25 cm'l} were exposed 100 to 1 mM cyslea~ mine (Sigma, SI. Louis) for up 10 two hours al 37"C. The cells were harveslrd by trypsinization, washed three limes with phosphateburrered ~aline. and auayed for cystinr with the cY!Hinc-hinding protein metlUld'1fl and for protein with the method (If Lowry et al. 21 Culture plal('~ were examincd frcqucntly hy I'ha!!("·cuntra:l:t microscopy during Ihis experiment. Scveral plates wefe fixed in glutaraldehyde and examined by electron micro~copy.
Studies In Animals
Cysteamine cyedrops, 0.11 percent (10 mM) or 0.55 percent (50 mM), were prepared under sterile conditions in normal saline solution without preservatives and were placed in one eye in eight albino rabbits every hour, eight hours daily, for 21 days. Normal saline drops were placed in the other eye as part of the randomized and blinded trial. The anim31s were examined daily for conjunctival injection and other adversc ophthalmologic errects. At the el\d of the trial, the rahbits were killrd and routine histologic examination of the ocular tissues was performed wilh a light microscope. After approval hy the' National Eye Institute institutional review board, a double-hlind, randomized trial of 0.11 perct:nI (10 mM) cysteamine eyt"drops in normal saline, as compared with normal salinc alone, w;u inilialrd. One drop of cystramine in nurmal saline was placed in one eyr, randomly selecl('d, hnurl)' while Ihe subjrct was awake. Normal saline alune was placed in the other eye according to the SAme schedule. Two young children wilh nephropalhic cystinosis, whose corneas had not yet become packed with cystine but did contain viJ'ihle cry~tals on slit-lamp biomicroscopy, were enrolled in the study. An ophthalmic nurse taught their mothers how 10 maintain sterililY in administering the eyedrops and how 10 maintain records of each application on a form supplifii to them. I-'rrsh hottles uf eyrdropJ' were used every live days to reduce the risk of COIHaminatinn. The ocular evaluation included slit. lamp biomicroscopy and photography, which wu extremely difficult because of the variable and inconsistent cooperation of the very young children. A Zeiss phutoslit lamp with stereoscopic accessories, beam spliuers, twin camera bodies, and sidt:-arm adaplcn was employed. Dircct focal illumination with a moderately wide slit beam (5 mm), an aperlure selting at f/22 or r/32, a Rash-intensity setting of 2, EktAchrome 200 film, and optimal mAgnification (25X) was used except where specifically noted.
Pallenls
Patient J was a white boy first seen at the Natinnal hlJ'tilutes of Health at the age of 14 months. The diagnosis uf nel,hrupathic cystinosis was confirmed by a leukocyte cysline level of 10 nmol of half·cystine per milligram of protein (normal, ~0.2). Oral cysteamine therapy (60 mg per kilogram of body weight per day) subsequently maintained leukocyte cystine levels (measured five hours aner a dlJse) ht'luw I nmol of half-cystine per milligram of protein.
On initial ophthalmic examinatinl1 at 14 months of age, sparse corneal crystal~ wrre evident on stereophotography.
Patient 2 was a white girl first seen at the National In~titutes of Health at the age of 13 months. The dingnosis of n<,phropathic cystinosis was made at II months of age on the basis of a leukocyte cystine level of 6.9 nmol of half-cystine per milligram of protein. Treatment with ond cysteamine was begun at 13 mondls of age, and by I.S month~ the palient WRS receiving approximately 70 mg of cysteamine per kilogram pcr day Rlld the leukocyte cystine level was approximatdy I nmol of half-cystine per milligram of protein. Slitlamp biomicfO!!copical examination at the aRC of 13 lIIonths revealed bilateral and symmetrical corneal crystal deposition.
RESULTS
In Vllro Siudies
The nonprotein cystine con lent of the cells ranged from 11.0 to 38.7 nmol of half-cysline per milligram of protein in three different cultures, as compared with a published value of 0.98 nmol of half-cystine per milligram of protcin in cultured corneal stromal cells from an adult patient with cystinosis. 22 The normal control value in the present study was 0.27 nmol of halfcystine per milligram of protein, and published normal values are less than 0.4. 22 When exposed to I mM cysteamine, the cystinotic corneal cells lost 82 percent of their cystine within 30 minutes and 96 percent within two hours (Fig. I) from normal cells on examination by either light or electron microscopy. The cclls contained regular microorganelles and numerous inclusion bodies. There were no specific morphologic alterations attrihutable to cysteaminc exposure.
Siudies In Animals
Daily clinical evaluation and a complete histopathological examination of the rabbits' ocular tissues were performed aller 21 days of eyed",p administration in eight animals. No dHferences between cysteamine-treated and normal saline-treated eyes were observed (data not shown).
In Vivo Siudies
In Patient I, sparse corneal crystals present at 14 months were difficult to observe because of poor cooperation but were documented photographically in the one eye (the right) that could be photographed. By 18 months, however, crystals were evident on slit-lamp biomicroscopy as well as photography and were present in similar amounts in both eyes. The crystals remained in both eyes until the patient was enrolled in the eysteamine-eyedrop protocol at 21 months or age (Fig. 2a) . After one month or therapy, there was a clinical impression of a decrease in the number of crystals in the right eye. Aller three months, the dilTercnee between the two eyes was evident, and by five months, the right central cornea appeared to be free of crystals, whereas the crystal deposition in the left cornea was unchanged (Fig. 2b) . These findings were documented photographically and confirmed on slitlamp biomicroscopy by three independent ophthalmologists who were unaware of the identity of the cysteamine-treated eye ali(I had not consulted hefore their evaluations.
After five months of therapy, because or the marked discrepancy in the crystal content betwecn the two eyes, it was considered inappropriate to continue the current treatment of the left eye. After approval was obtained from the National Eye Institute institutional review board, the drops being used in the right eye were also administered to the left eye. Three weeks later, the code for the eyedrops was broken to reveal that the right eye had been treated with cysteamine. In Patient 2, corneal crystal accumulation progressed in both eyes between the ages of 13 months (Fig. 3a) and 19 months (Fig. 3b) , one month before cysteamine treatment. After four months of treatment, the patient had a marked reduction in the number of corneal crystals in the right eye, whereas the number in the left eye was not markedly reduced (Fig. 3c) . These findings were confirmed by four independent ophthalmologists who were unaware of which eye had been treated. Breaking the code revealed that the right eye had been treated with cysteamine.
No clinical toxicity was observed as a result of topical ophthalmic cysteamine. In particular, there was no conjunctival injection or soft-tissue irritation. Neither parents nor physicians could identify the cysteamine eyedrops by smell, apparently because the solution of free thiol was very dilute. Compliance was determined to be excellent according to the history 'and review of the data forms on eyedrop administration maintained by the parents.
DISCUSSION
Cysteamine has been employed since 1978 as a cystine-depleting agent in cystinosis. Cysteamine passes through plasma and lysosomal membranes and, because it is a weak base, concentrates within acidic Iysosomes. There, it reacts with cystine to form cysteine and a cysteine-cysteamine mixed disulfide, both of which traverse the cystinotic lysosomal membrane in a normal fashion.4,23 In fact, the mixed disulfide leaves by virtue of its stearic resemblance to lysine, whose lysosomal membrane-transport system functions normally in cystinotic cells cultured in vitro. 24 In vivo, oral cysteamine readily depletes peripheralleu~ kocytes of 90 percent of their endogenous cystine content I6 and has proved efficacy in maintaining renal function and normalizing growth rates in children with cystinosis.I systemic cysteamine does not prevent corneal crystal accumulation. However, corneal stromal cells from a patient with nephropathic cystinosis were substantially depleted of cystine by cysteamine in vitro (Fig. I) . In this res:)cct (hev resembled cvstinotic fibroblasts 1fj and renal ~c1l52S t;eated similarly. :\tIoreover, in vivo s(Uciies rc\·ealed that both Patients I and 2 had an absolute reduction in the number of corneal cystine crystals after topical cysteamine therapy for five and four months, respectively ( Fig. 2 and 3 ). In fact, nearly all the crystals had been removed from the cysteamine-treated corneas ( Fig. 2b and 3b) . The possibility remains chat oral cysteamine reduced the number of corneal crystals in treated pa-tients, but that the change was imperceptible against a background or hundreds or thousands or crystals per cornea. If so, the reduction in crystals attributable to oral cysteamine must have been minimal, since there was a negligible change in crystal density between 14 and 21 months of age in Patient I. Furthermore, the number of corneal crystals actually in· creased between 13 and 19 months of age in Patient 2 ( Fig. 3a and 3b) .
One explanation for the dilTercnce in errectiveness between topical and oral cysteamine is derived from the raetthat the cornea does not have a blood supply. Because· of this, a cystine-depleting concentration of orally administered cysteamine could not reach corneal stromal cells; topical administration of cysteamine would obviate this problem. It should also be noted that the concentration of cysteamine in the eyedrops, 10 mM, is approximately 20 times the maximum level or cysteamine achieved in the blood or children receiving standard oral doses or the drug.'· The very high local concentration of cysteamine at the cornea certainly contributed to its ability to dissolve the cystine crystal,.
We deliberately selected young patients with cystinosis whose corneas were only moderately filled with crystals, so that the difference between the treated and untreated eyes would be apparent. The demonstrated emcacy or cysteamine eyedrops in these children does not mean that older cystinotic patients with packed corneas will realize the same benefit. In particular, we do not know what effect cysteamine eycdrops will have on the corneal clouding and recurrent corneal erosions that plague many patients with cystinosis arter renal transplantation. 9 • 1 :', Two important findings rollow rrom the results reported here. First, the efficacy of cysteamine eyedrops in dissolving corneal crystals demonstrates that a cystinotic organ can be depleted or cystine (in crystalline or noncrystalline rorm) by cysteamine. Previous in vivo investigations have been limited to demonstrating cystine depletion in circulating leukocytes. IIl • 17 The present findings suggest that oral cysteamine, ir adequately delivered to target tissues, could dissolve crystals in certain cystinotic organs, just as topically delivered cysteamine eyedrops removed cystine crystals rrom the cornea. Second, the lack of adverse reactions to topical cysteamine in animals and children and its cystine-depleting efficacy make cysteamine eyedrops the treatment or choice for corneal crystals in young children with cystinosis wh~)se parents can comply with a rairly demanding regImen.
Despite these encouraging results, several CJuestions require investi.~aliol1. For example, is hourly administration required? Is 10 mM the optimal concentration of cysteamine to employ? Will older children benefit rrom this therapeutic regimen? "Viii our two patients avoid some of the later ocular complications or cystinosis, sllch as photophobia, corneal clouding, and re· current corneal erosions, hy virtue or cysteamine treatment of their corneas? The answers to these questions will require years or study, but we now have a strong impetus to pursue them. 
